Tianeptine and fluoxetine in major depression: a 6‐week randomised double‐blind study

Vladimir Novotny; Frantisek Faltus

doi:10.1002/hup.411

journal article Jun 27, 2002

Tianeptine and fluoxetine in major depression: a 6‐week randomised double‐blind study

Vladimir Novotny Frantisek Faltus

Human Psychopharmacology: Clinical and Experimental Vol. 17 No. 6 pp. 299-303 · Wiley

View at Publisher Save 10.1002/hup.411

Abstract

AbstractIn a 6‐week, multicentre, randomised, double‐blind controlled study, tianeptine (37.5 mg/day) and fluoxetine (20 mg/day) were compared for efficacy and safety in 178 patients with major depression. No significant difference was shown between the two drugs, either in terms of efficacy (MADRS, CGI, COVI) or in terms of safety, except for the CGI ‘severity of illness’ which was lower at the end point with tianeptine than with fluoxetine. The percentages of responders (as defined by a 50% decrease of the MADRS score from baseline to end point) were 75% with tianeptine and 67% with fluoxetine, showing the efficacy of both drugs. In conclusion, both tianeptine and fluoxetine are effective and well‐tolerated treatments for major depression. Copyright © 2002 John Wiley & Sons, Ltd.

Topics

No keywords indexed for this article. Browse by subject →

References

25

[1]

10.1016/0924-977x(93)90110-8

[2]

Altamura AC "The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression" Br J Psychiatry (1988) 10.1192/s0007125000297377

[3]

American Psychiatric Association (1994)

[4]

10.3109/10401239309148983

[5]

Bobon DP "Contribution de l'échelle AMDP à la psychopathologie quantitative" Acta Psychiatr Belg (1985)

[6]

10.1016/0924-9338(96)82332-7

[7]

10.1159/000119326

[8]

10.1016/0364-7722(79)90006-7

[9]

Dalery J "Efficacy of tianeptine versus placebo in the long‐term treatment of unipolar major recurrent depression" Encephale (1997)

[10]

10.1016/s0924-9338(00)94766-7

[11]

10.1159/000118590

[12]

Guy W (1976)

[13]

Hall J "Fluoxetine: efficacy against placebo and by dose—an overview" Br J Psychiatry (1988) 10.1192/s0007125000297304

[14]

Kato G "Profil neurochimique de la tianeptine, un nouvel antidepresseur" Clin Neuropharmacol (1988)

[15]

10.1001/archpsyc.1994.03950010008002

[16]

10.1002/hup.289

[17]

10.1016/s0165-0327(99)00009-9

[18]

10.1016/s0014-2999(99)00163-6

[19]

Mennini T "Acute noise stress reduces (3h) 5‐hydroxytryptamine uptake in rat brain synaptosomes: projective effects of buspirone and tianeptine" Eur J Pharmacol (1993)

[20]

A New Depression Scale Designed to be Sensitive to Change

Stuart A. Montgomery, Marie Åsberg

British Journal of Psychiatry 10.1192/bjp.134.4.382

[21]

10.1080/13651500152048414

[22]

10.1136/bmj.306.6879.683

[23]

Szádóczky E "Efficacy and acceptability of tianeptine and sertraline in acute treatment phase of depression" Neuropsychopharmacol Hung (2000)

[24]

10.2165/00023210-200115030-00006

[25]

Waintraub L "Efficacy and safety of tianeptine in major depression: evidence from a 3‐month controlled clinical trial versus paroxetine" Eur Neuropsychopharm (2000)

Metrics

23

Citations

25

References

Details

Published: Jun 27, 2002
Vol/Issue: 17(6)
Pages: 299-303
License: View

Authors

Cite This Article

Vladimir Novotny, Frantisek Faltus (2002). Tianeptine and fluoxetine in major depression: a 6‐week randomised double‐blind study. Human Psychopharmacology: Clinical and Experimental, 17(6), 299-303. https://doi.org/10.1002/hup.411

Tianeptine and fluoxetine in major depression: a 6‐week randomised double‐blind study

You May Also Like